| | | | | | | | | | |
|
| |
|
| Dockets Entered
On November 22, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| 2005D-0356
|
| Guidance for Industry: Questions and Answers Regarding the Final Rule on Establishment and Maintenance of Records
|
|
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| 2005N-0153
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Regulations For In Vivo Radiopharmaceuticals Used For Diagnosis and Monitoring
|
|
|
|
|
| 2005N-0343
|
| Agency Emergency Processing Under OMB Review; Guidance for Requesting an Extension to Use Existing Label Stock after the Trans Fat Labeling Effective Date of January 1, 2006
|
|
|
|
|
| 2005P-0305
|
| Remove Dietary Supplements that Contain the Drug Pyridoxamine
|
|
|
|
|
| 2005P-0472
|
| ANDA for Ramipril Instant Release Oral Tablets
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| C
93
|
| Embry Farm Service
|
| Vol #:
|
| 17
|
|
|
|
|
| C 94
|
| Eligible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 95
|
| H. Graver, Jr.
|
| Vol #:
|
| 17
|
|
|
|
|
| C 96
|
| J and R Rutt
|
| Vol #:
|
| 17
|
|
|
|
|
| C 97
|
| A. Andreol
|
| Vol #:
|
| 17
|
|
|
|
|
| C 98
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 99
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 100
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 101
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 102
|
| J. Avila
|
| Vol #:
|
| 17
|
|
|
|
|
| C 103
|
| L. Ryas
|
| Vol #:
|
| 17
|
|
|
|
|
| C 104
|
| S. Nova
|
| Vol #:
|
| 17
|
|
|
|
|
| C 105
|
| H. Romero
|
| Vol #:
|
| 17
|
|
|
|
|
| C 106
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 107
|
| Illegible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 108
|
| L. Cuartero
|
| Vol #:
|
| 17
|
|
|
|
|
| C 109
|
| D. Resendiz
|
| Vol #:
|
| 17
|
|
|
|
|
| C 110
|
| A. Lota
|
| Vol #:
|
| 17
|
|
|
|
|
| C 111
|
| B. Sikes
|
| Vol #:
|
| 17
|
|
|
|
|
| C 112
|
| M. Leid
|
| Vol #:
|
| 17
|
|
|
|
|
| C 113
|
| L. Quadowine
|
| Vol #:
|
| 17
|
|
|
|
|
| 2005D-0356
|
| Guidance for Industry: Questions and Answers Regarding the Final Rule on Establishment and Maintenance of Records
|
|
|
|
|
| GDL
2
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
2
|
| FDA
|
| Vol #:
|
| 1
|
|
| |
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| CS 3
|
| HFA-305
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
| |
|
| MO 3
|
| GCF-1
|
| Vol #:
|
| 1
|
|
|
|
|
| OR 3
|
| HF-3 to TMJ Implants, Inc.
|
| Vol #:
|
| 1
|
|
| |
|
| 2005N-0153
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Regulations For In Vivo Radiopharmaceuticals Used For Diagnosis and Monitoring
|
|
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0343
|
| Agency Emergency Processing Under OMB Review; Guidance for Requesting an Extension to Use Existing Label Stock after the Trans Fat Labeling Effective Date of January 1, 2006
|
|
|
|
|
| N
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0305
|
| Remove Dietary Supplements that Contain the Drug Pyridoxamine
|
|
|
|
|
| N
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0472
|
| ANDA for Ramipril Instant Release Oral Tablets
|
|
|
|
|
| ACK
1
|
| HFA-305 to Pharmaceutical Patent Attorneys, LLC
|
| Vol #:
|
| 1
|
|
|
|
|
| CP
1
|
| Pharmaceutical Patent Attorneys, LLC
|
| Vol #:
|
| 1
|
|
